Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  Hypertension

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 30 articles:
HTML format



Single Articles


    March 2026
  1. KASUJJA FX, Aikaeli F, Garrib A, van Widenfelt E, et al
    Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.
    Lancet. 2026;407:1084-1094.
    PubMed     Abstract available


  2. AZIZI M, Brown JM, Dwyer JP, Flack JM, et al
    Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet. 2026;407:988-999.
    PubMed     Abstract available


  3. MAHFOUD F, Lauder L
    Aldosterone synthase inhibition in resistant hypertension: promises and unknowns.
    Lancet. 2026;407:922-923.
    PubMed    


    February 2026
  4. AZIZI M, Tuttle KR, Brown JM, Piskorz DL, et al
    New drug therapies for hypertension.
    Lancet. 2026 Feb 10:S0140-6736(25)02064-1. doi: 10.1016/S0140-6736(25)02064.
    PubMed     Abstract available


    November 2025
  5. FARRAR J, Frieden T
    WHO global report on hypertension 2025.
    Lancet. 2025;406:2318-2319.
    PubMed    


    August 2025
  6. WANG N, Salam A, Pant R, Kumar A, et al
    Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials.
    Lancet. 2025;406:915-925.
    PubMed     Abstract available


  7. MCEVOY JW
    Optional hypertension: a new concept emerging from trials of intensive blood pressure control.
    Lancet. 2025 Aug 28:S0140-6736(25)01670-8. doi: 10.1016/S0140-6736(25)01670.
    PubMed    


  8. GUO X, Sun G, Xu Y, Zhou S, et al
    Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
    Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
    PubMed     Abstract available


    May 2025
  9. FRIEDEN TR, Garg R, Moran AE, Whelton PK, et al
    Improved hypertension care requires measurement and management in health facilities, not mass screening.
    Lancet. 2025 May 7:S0140-6736(25)00561-6. doi: 10.1016/S0140-6736(25)00561.
    PubMed     Abstract available


    January 2025
  10. MCCARTHY CP, Bruno RM, Rahimi K, Touyz RM, et al
    Global and European landscape of major hypertension guidelines.
    Lancet. 2025 Jan 15:S0140-6736(24)02795-8. doi: 10.1016/S0140-6736(24)02795.
    PubMed    


    October 2024
  11. RODGERS A, Salam A, Schutte AE, Cushman WC, et al
    Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical tria
    Lancet. 2024;404:1536-1546.
    PubMed     Abstract available


  12. ANTONOPOULOU M, Chliveros K
    A novel low-dose triple single-pill combination for hypertension.
    Lancet. 2024;404:1496-1498.
    PubMed    


    August 2024

  13. General and abdominal adiposity and hypertension in eight world regions: a pooled analysis of 837 population-based studies with 7.5 million participants.
    Lancet. 2024;404:851-863.
    PubMed     Abstract available


    July 2024
  14. WERNHART M, Wiesinger C, Windpessl M, Madl-Liebenberger L, et al
    A visual diagnosis of phaeochromocytoma crisis characterised by cyclic fluctuations of blood pressure: be on the look-out for rapid changes.
    Lancet. 2024;404:375-376.
    PubMed    


  15. RAHIMI K
    Mounting evidence in favour of the lower, the better blood pressure paradigm.
    Lancet. 2024;404:216-217.
    PubMed    


    June 2024
  16. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    PubMed     Abstract available


  17. HAYASHI SI, Kawano Y, Morishita R, Kusano KF, et al
    Time-lagged amelioration of vascular endothelial function in malignant hypertension: different organs improved at different rates.
    Lancet. 2024;403:2630-2631.
    PubMed    


    May 2024
  18. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    PubMed    


  19. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    PubMed    


  20. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    PubMed    


    March 2024
  21. BAUDIN E, Goichot B, Berruti A, Hadoux J, et al
    Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
    Lancet. 2024;403:1061-1070.
    PubMed     Abstract available


  22. DE LA SIERRA A, Staplin N, Ruilope LM, Baigent C, et al
    Ambulatory blood pressure monitoring and mortality - Authors' reply.
    Lancet. 2024;403:812.
    PubMed    


  23. LIU W, Ge W, Fan X, Du Y, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:811-812.
    PubMed    


  24. MARTINEZ-GARCIA MA, Pengo MF, Parati G
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810-811.
    PubMed    


  25. CHU WM, Ho HE, Wei JC
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:810.
    PubMed    


  26. LI SQ, Zhou JP, Wang Y, Li QY, et al
    Ambulatory blood pressure monitoring and mortality.
    Lancet. 2024;403:809-810.
    PubMed    


    November 2023
  27. JACKSON R, Rodgers A
    The ESH guidelines and missed prevention opportunities.
    Lancet. 2023;402:1729-1730.
    PubMed    


    October 2023
  28. MESSERLI FH, Bangalore S, Mandrola JM
    beta blockers switched to first-line therapy in hypertension.
    Lancet. 2023 Oct 13:S0140-6736(23)01733-6. doi: 10.1016/S0140-6736(23)01733.
    PubMed     Abstract available


  29. KIVUYO S, Birungi J, Okebe J, Wang D, et al
    Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial.
    Lancet. 2023;402:1241-1250.
    PubMed     Abstract available


  30. KISIGO GA, Peck RN
    Integrating HIV, hypertension, and diabetes primary care in Africa.
    Lancet. 2023;402:1211-1213.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hypertension is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum